Arkolith/Insider Trading/ELYM/Form 4

Morisset Valerie

EVP, R&D and CSOEliem Therapeutics, Inc. (ELYM) · full profile →Form 4 · filed Mar 14, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 10, 2023Option exercise(M)255K—$0406K
Mar 10, 2023Option exercise(M)61K—$0467K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 10, 2023Option exercise(M)255K—$05K
Mar 10, 2023Option exercise(M)61K—$061K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-018531) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML